https://www.selleckchem.com/pr....oducts/fatostatin.ht
Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized controlled trials are needed to determine the safety and efficacy of HCQ for the treatment of hospitalized patients with COVID-19. We conducted a multicenter, double-blind randomized clinical trial of HCQ among patients hospitalized with laboratory-confirme
Like
Comment
Share
